期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 18, 期 16, 页码 1861-1870出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v18.i16.1861
关键词
Ulcerative colitis; Inflammatory bowel disease; Infliximab; Surgery; Laparoscopy; Single incision laparoscopy; Total abdominal colectomy; Ileal pouch anal anastomosis; Restorative proctocolectomy
Recently introduced in the treatment algorithms and guidelines for the treatment of ulcerative colitis, biological therapy is an effective treatment option for patients with an acute severe flare not responsive to conventional treatments and for patients with steroid dependent disease. The reduction in hospitalization and surgical intervention for patients affected by ulcerative colitis after the introduction of biologic treatment remains to be proven. Furthermore, these agents seem to be associated with increase in cost of treatment and risk for serious postoperative complications. Restorative proctocolectomy with ileal pouch-anal anastomosis is the surgical treatment of choice in ulcerative colitis patients. Surgery is traditionally recommended as salvage therapy when medical management fails, and, despite advances in medical therapy, colectomy rates remain unchanged between 20% and 30%. To overcome the reported increase in postoperative complications in patients on biologic therapies, several surgical strategies have been developed to maintain long-term pouch failure rate around 10%, as previously reported. Surgical staging along with the development of minimally invasive surgery are among the most promising advances in this field. (C) 2012 Baishideng. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据